Phadia

Country Sweden
Region Ostra Mellansverige
Investor Cinven

Phadia, based in Sweden, is a leading in-vitro allergy diagnostics and autoimmunity diagnostics business. Private equity firm Cinven acquired the company in 2007 with a strategy to assist Phadia in growing its core business to reach its full potential, both strategically and operationally. This involved product development; accelerating revenue growth via expansion and professionalisation of the sales force, particularly in the US; and supporting internationalisation into emerging markets such as India, China and Brazil.

Under Cinven's ownership, Phadia became a true global leader, distributing directly in 21 territories across the world and enjoying further reach through a broad international network of distributors. When Cinven sold the company in 2011, it employed 1,500 people worldwide.

We have forged a very close partnership with Cinven who have brought real sector insight, clarity of thinking to our strategy, and hands-on support.

Magnus Lundberg, CEO, Phadia

What did the business need?

  • Geographic expansion in high-potential and under-penetrated markets
  • Investment in R&D and sales force
  • Improvements in organisational effectiveness

How did private equity backing create lasting value?

  • Best in class practices implemented across regions to drive efficiency and organisational effectiveness
  • Expansion and optimisation of the sales force in high-potential regions
  • Enhanced monitoring and targeting processes
  • Roll-out of Phadia’s full product range into the US
  • Accelerated expansion in emerging markets, particularly in China and India
  • Acquisition of Phadia’s Chinese distributor and setting up an Indian office

What outcomes did private equity investment achieve?

  • Sale of Phadia to trade buyer Thermo Fisher Scientific in May 2011 for €2.47bn
  • 3.4x return for investors in Cinven’s fund
  • Doubling the revenue growth rate, with EBITDA up from €96m to €146m during investment
  • Headcount increase from 1,000 in 2007 to around 1,500 in 2011
  • Phadia had more than 5,000 systems installed in more than 3,000 labs by 2011

€1bn

capital gain for investors in Cinven’s fund

50%

increase in headcount

Case study image

For more info
Phadia
Cinven

We've updated our privacy policy in response to the General Data Protection Regulation (GDPR) effective as of 25 May 2018. You can review our updated privacy policy and if you have any comments please contact us.

I have reviewed the updated Privacy Policy